![ISPOR 2024 May 5-8, 2024 | Atlanta, GA, USA. Early Registration Rate expires March 28.]({"type":"image" , "src" : "/sda/112343/IJME-March-May.jpg"})
Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Alison Stopeck, Adam Brufsky, Lisa Kennedy, Sumi Bhatta, Debajyoti Bhowmik, Jacqueline Buchanan, Nicolas Despiegel & Guy Hechmati. (2020) Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. Journal of Medical Economics 23:1, pages 37-47.
Read now
Read now
Evangelos Terpos, Aurelien Jamotte, Alexandra Christodoulopoulou, Marco Campioni, Debajyoti Bhowmik, Lisa Kennedy & Wolfgang Willenbacher. (2019) A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy. Journal of Medical Economics 22:8, pages 766-776.
Read now
Read now
Noopur Raje, Garson David Roodman, Wolfgang Willenbacher, Kazuyuki Shimizu, Ramón García-Sanz, Evangelos Terpos, Lisa Kennedy, Lorenzo Sabatelli, Michele Intorcia & Guy Hechmati. (2018) A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. Journal of Medical Economics 21:5, pages 525-536.
Read now
Read now
Thomas E. Delea, Jordan Amdahl, Diana Boyko, May Hagiwara, Zachary F. Zimmerman, Janet L. Franklin, Ze Cong, Guy Hechmati & Anthony Stein. (2017) Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective. Journal of Medical Economics 20:9, pages 911-922.
Read now
Read now
Joaquim Cristino, Jíndřich Finek, Petra Jandova, Martin Kolek, Bálint Pásztor, Christina Giannopoulou, Yi Qian, Tomas Brezina & Mickael Lothgren. (2017) Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic. Journal of Medical Economics 20:8, pages 799-812.
Read now
Read now
Athanasios Dellis & Athanasios Papatsoris. (2016) Cost–effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer. Expert Review of Pharmacoeconomics & Outcomes Research 16:1, pages 5-10.
Read now
Read now
D. V. Byreddy, M. F. Bouchonville II & E. M. Lewiecki. (2015) Drug-induced osteoporosis: from Fuller Albright to aromatase inhibitors. Climacteric 18:sup2, pages 39-46.
Read now
Read now
Athanasios Dellis & Athanasios G Papatsoris. (2014) The economics of abiraterone acetate for castration-resistant prostate cancer. Expert Review of Pharmacoeconomics & Outcomes Research 14:2, pages 175-179.
Read now
Read now
Jipan Xie, Melissa Diener, Rachael Sorg, Eric Q. Wu & Madhav Namjoshi. (2013) Letter to the editor. Journal of Medical Economics 16:2, pages 260-263.
Read now
Read now
Sonya J. Snedecor, John A. Carter, Satyin Kaura & Marc F. Botteman. (2013) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A cost-effectiveness analysis. Journal of Medical Economics 16:1, pages 19-29.
Read now
Read now
Draupadi B Talreja. (2012) Importance of antiresorptive therapies for patients with bone metastases from solid tumors. Cancer Management and Research 4, pages 287-297.
Read now
Read now
Articles from other publishers (33)
Xiaoting Huang, Yiwei Liu, Shen Lin, Hang Wang, Yujie Deng, Xin Rao, Xianzhong Guo, Xinchan Jiang, Xiuhua Weng & Pinfang Huang. (2023) Adjuvant zoledronic acid therapy for postmenopausal women with early breast cancer in China: a cost-effectiveness analysis. International Journal for Quality in Health Care 35:2.
Crossref
Crossref
Aaron P. Mitchell, Akriti Mishra Meza, Katherine S. Panageas, Allison Lipitz-Snyderman, Azeez Farooki & Michael J. Morris. (2022) Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases 26:1, pages 126-132.
Crossref
Crossref
Conor McCloskey, María Toboso Ortega, Sunita Nair, Maria João Garcia & Federico Manevy. (2022) A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting. PharmacoEconomics - Open 7:1, pages 3-36.
Crossref
Crossref
Bolin Ren, Xiaolei Ren, Lu Wang, Chao Tu, Wenchao Zhang, Zhongyue Liu, Lin Qi, Lu Wan, Ke Pang, Cheng Tao & Zhihong Li. (2022) A bibliometric research based on hotspots and frontier trends of denosumab. Frontiers in Pharmacology 13.
Crossref
Crossref
Vinod Patel, Megan Burns, Sheelen Patel, Sanford Grossman, Rana Wali, Isabel Sassoon, Elias Pintus & Marianne Henien. (2022) The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 3: prostate cancer. British Dental Journal.
Crossref
Crossref
Megan M. Tu, Mark Clemons, Carol Stober, Ahwon Jeong, Lisa Vandermeer, Mihaela Mates, Phillip Blanchette, Anil Abraham Joy, Olexiy Aseyev, Gregory Pond, Dean Fergusson, Terry L. Ng & Kednapa Thavorn. (2021) Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer. Current Oncology 28:3, pages 1847-1856.
Crossref
Crossref
Daniel B. Rosen, Cory D. Benjamin, Joanna C. Yang, Connor Doyle, Zhigang Zhang, Chris A. Barker, Max Vaynrub, T. Jonathan Yang & Erin F. Gillespie. (2020) Early palliative radiation versus observation for high-risk asymptomatic or minimally symptomatic bone metastases: study protocol for a randomized controlled trial. BMC Cancer 20:1.
Crossref
Crossref
Tsung-Ying Lee, Hsuan-Ying Chen, Tsai-Yun Chen, Sin-Syue Li, Wei-Tse Fang, Yao-Chun Wen, Yu-Wen Lo & Huang-Tz Ou. (2020) Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan’s health care system. The European Journal of Health Economics 21:7, pages 1105-1116.
Crossref
Crossref
Sikander Ailawadhi, Rohan Medhekar, Nicole Princic, Robert Fowler, Oth Tran, Debajyoti Bhowmik & Sumeet Panjabi. (2019) Healthcare resource utilization and costs in patients with multiple myeloma with and without skeletal-related events. Journal of Oncology Pharmacy Practice 26:5, pages 1070-1079.
Crossref
Crossref
Jessica Y. Matuoka, James G. Kahn & Silvia R. Secoli. (2018) Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review. The European Journal of Health Economics 20:4, pages 487-499.
Crossref
Crossref
Thomas Grochtdreis, Hans-Helmut König, Alexander Dobruschkin, Gunhild von Amsberg & Judith Dams. (2018) Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review. PLOS ONE 13:12, pages e0208063.
Crossref
Crossref
Syril D. Pettit & Rebecca Kirch. (2018) Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?. Cardio-Oncology 4:1.
Crossref
Crossref
Alexander M. Won, Prajwal Boddu, Adegbenga O. Otun, Ruth Aponte-Wesson & Mark Chambers. (2018) Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 126:4, pages e208-e211.
Crossref
Crossref
Amr Menshawy, Omar Mattar, Ali Abdulkarim, Shiref Kasem, Noha Nasreldin, Esraa Menshawy, Salahuddean Mohammed, Mohamed Abdel-Maboud, Mohamed Gadelkarim, Gehad Gamal El Ashal & Ahmed Saber Elgebaly. (2018) Denosumab versus bisphosphonates in patients with advanced cancers-related bone metastasis: systematic review and meta-analysis of randomized controlled trials. Supportive Care in Cancer 26:4, pages 1029-1038.
Crossref
Crossref
Lazaros Andronis, Ilias Goranitis, Sue Bayliss & Rui Duarte. (2017) Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review. PharmacoEconomics 36:3, pages 301-322.
Crossref
Crossref
Charles L. ShapiroJames P. MoriartyStacie DusetzinaAndrew L. HimelsteinJared C. FosterStephen S. GrubbsPaul J. NovotnyBijan J. Borah. (2017) Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). Journal of Clinical Oncology 35:35, pages 3949-3955.
Crossref
Crossref
Jan Norum & Carsten Nieder. (2017) Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence. PharmacoEconomics 35:12, pages 1223-1236.
Crossref
Crossref
I. Duran, M.G. Fink, A. Bahl, H. Hoefeler, A. Mahmood, D. Lüftner, H. Ghazal, R. Wei, K.C. Chung, G. Hechmati, J. Green & C. Atchison. (2017) Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study. European Journal of Cancer Care 26:6, pages e12452.
Crossref
Crossref
Zhicai Zhang, Feifei Pu & Zengwu Shao. (2017) The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials. Journal of Bone Oncology 9, pages 21-24.
Crossref
Crossref
Fengxia Chen & Feifei Pu. (2016) Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials. Oncology Research and Treatment 39:7-8, pages 453-459.
Crossref
Crossref
Gianfranco Favia, Angela Tempesta, Luisa Limongelli, Vito Crincoli & Eugenio Maiorano. (2016) Medication-Related Osteonecrosis of the Jaws: Considerations on a New Antiresorptive Therapy (Denosumab) and Treatment Outcome after a 13-Year Experience. International Journal of Dentistry 2016, pages 1-9.
Crossref
Crossref
Kristen Bink. (2015) Analysis of Denosumab on Skeletal-Related Events in Patients With Advanced Breast Cancer. Clinical Journal of Oncology Nursing 19:5, pages E108-E114.
Crossref
Crossref
Miguel Ángel Seguí, Ignacio Durán, Celia Roldán, Itziar Oyagüez, Miguel Ángel Casado, Laura Gutiérrez, José Antonio Gasquet & Dolores Isla. (2014) Análisis del impacto presupuestario de denosumab para la prevención de eventos relacionados con el esqueleto en adultos con metástasis óseas de tumores sólidos en España. PharmacoEconomics Spanish Research Articles 12:3, pages 83-92.
Crossref
Crossref
Joseph F. LevyPatrick D. MeekMarjorie A. Rosenberg. (2014) US-Based Drug Cost Parameter Estimation for Economic Evaluations. Medical Decision Making 35:5, pages 622-632.
Crossref
Crossref
Alessandro Cappetta, Laura Spano, Laura Evangelista, Stefania Zovato, Giuseppe Opocher & Davide Pastorelli. (2015) Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid. Anti-Cancer Drugs 26:2, pages 232-235.
Crossref
Crossref
Candice Yong, Eberechukwu Onukwugha & C. Daniel Mullins. (2014) Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer. Current Opinion in Oncology 26:3, pages 274-283.
Crossref
Crossref
Janet E. Brown, Liang Zeng & Caroline Wilson. 2014. Bone Metastases. Bone Metastases
95
124
.
Thomas Roza, Lukman Hakim, Hendrik van Poppel & Steven Joniau. (2013) Bone-Targeted Therapies for Elderly Patients with Renal Cell Carcinoma: Current and Future Directions. Drugs & Aging 30:11, pages 877-886.
Crossref
Crossref
Kaitlin Koo, Kinsey Lam, Nicole Mittmann, Andre Konski, Kristopher Dennis, Liang Zeng, Henry Lam & Edward Chow. (2013) Comparing cost-effectiveness analyses of denosumab versus zoledronic acid for the treatment of bone metastases. Supportive Care in Cancer 21:6, pages 1785-1791.
Crossref
Crossref
Roger von Moos, Cora Sternberg, Jean-Jacques Body & Carsten Bokemeyer. (2013) Reducing the burden of bone metastases. Supportive Care in Cancer 21:6, pages 1773-1783.
Crossref
Crossref
John A. Ford, Rob Jones, Andrew Elders, Clive Mulatero, Pamela Royle, Pawana Sharma, Fiona Stewart, Radha Todd & Graham Mowatt. (2013) Denosumab for treatment of bone metastases secondary to solid tumours: Systematic review and network meta-analysis. European Journal of Cancer 49:2, pages 416-430.
Crossref
Crossref
Allan Lipton, Karim Fizazi, Alison T. Stopeck, David H. Henry, Janet E. Brown, Denise A. Yardley, Gary E. Richardson, Salvatore Siena, Pablo Maroto, Michael Clemens, Boris Bilynskyy, Veena Charu, Philippe Beuzeboc, Michael Rader, Maria Viniegra, Fred Saad, Chunlei Ke, Ada Braun & Susie Jun. (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. European Journal of Cancer 48:16, pages 3082-3092.
Crossref
Crossref
Miguel Martin, Richard Bell, Hugues Bourgeois, Adam Brufsky, Ingo Diel, Alexandru Eniu, Lesley Fallowfield, Yasuhiro Fujiwara, Jacek Jassem, Alexander H.G. Paterson, Diana Ritchie, Günther G. Steger, Alison Stopeck, Charles Vogel, Michelle Fan, Qi Jiang, Karen Chung, Roger Dansey & Ada Braun. (2012) Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid. Clinical Cancer Research 18:17, pages 4841-4849.
Crossref
Crossref